MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.78
+0.40
+1.71%
Opening 14:55 07/09 EDT
OPEN
23.35
PREV CLOSE
23.38
HIGH
23.82
LOW
22.75
VOLUME
291.48K
TURNOVER
--
52 WEEK HIGH
34.11
52 WEEK LOW
13.12
MARKET CAP
1.25B
P/E (TTM)
10.97
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SUPN stock price target is 28.00 with a high estimate of 33.00 and a low estimate of 24.00.

EPS

SUPN News

More
These 3 Biotech Stocks Are Outperforming Their Peers Here's Why
Investor's Business Daily · 2d ago
5 Things To Know If You Want To Beat The Market
Seeking Alpha - Article · 3d ago
Supernus Sues Apotex for Infringement of Oxtellar XR® Patents
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that earlier today it sued generic drug maker Apotex Inc. and Apotex Corp.
GlobeNewswire · 06/26 22:29
Supernus Pharmaceuticals Inc (SUPN): Hedge Funds Are Snapping Up
Insider Monkey · 06/18 15:19
Supernus' Makeover: A Work In Progress
Seeking Alpha - Article · 06/16 12:23
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $31
Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Neutral to Overweight and raises the price target from $25 to $31.
Benzinga · 06/16 09:10
Jefferies Reinstates Hold on Supernus Pharmaceuticals, Announces $24 Price Target
Jefferies analyst David Steinberg reinstates Supernus Pharmaceuticals (NASDAQ:SUPN) with a Hold and announces $24 price target.
Benzinga · 06/15 11:40
Top Pharmaceutical Stocks for Q3 2020
Investopedia · 06/11 17:27

Industry

Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.68%

Hot Stocks

Symbol
Price
%Change

About SUPN

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
More

Webull offers kinds of Supernus Pharmaceuticals Inc stock information, including NASDAQ:SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.